Cardio Diagnostics(NASDAQ) CDIOW

Cardio Diagnostics Holdings, Inc. is a biotechnology company founded in 2017, based in Chicago, Illinois. The company specializes in developing clinical tests that utilize epigenetics to evaluate cardiovascular disease risk, with a notable product being the Epi+Gen CHD test.

Products and Services

• Epi+Gen CHD test for predicting coronary heart disease risk
• Clinical tests leveraging epigenetic technology
• Innovative diagnostic tools for cardiovascular health assessment

Growth Outlook

• Market demand for cardiovascular diagnostics is increasing
• Expansion of product offerings anticipated in the coming years
• Strategic partnerships may enhance market reach and innovation

Financial Highlights

• Recent quarterly revenue of $2,680, reflecting ongoing development efforts
• Cash and cash equivalents of $7,077,021, providing operational flexibility
• Current ratio of 15.76 indicates strong liquidity position

Cardio Diagnostics Holdings, Inc. is positioned in a growing market focused on cardiovascular health, with innovative products that leverage cutting-edge technology. The company’s recent financial performance shows a commitment to research and development, although it is currently operating at a loss. The substantial cash reserves provide a buffer for ongoing operations and potential growth initiatives. With a strong current ratio, the company demonstrates a solid liquidity position, which is crucial for navigating the challenges of the biotechnology sector. As the demand for advanced diagnostic tools continues to rise, Cardio Diagnostics Holdings, Inc. may present an intriguing opportunity for investors interested in the healthcare and biotechnology industries.